<?xml version="1.0" encoding="UTF-8"?>
<p>The preparation of MVA vaccine stocks was performed by the infection of permissive CEF cells at low multiplicity of infection (M.O.I.). The supernatants were collected and the remaining cells lysed by successive rounds of freezing and thawing. The released virus was further concentrated by centrifugation through 36% (
 <italic>w</italic>/
 <italic>v</italic>) sucrose cushions and titres determined by routine plaque assay in DF-1 cell monolayers [
 <xref rid="B24-pathogens-08-00216" ref-type="bibr">24</xref>].
</p>
